DENOSUMAB-GCTB-P2

NCT00396149 📎

Regimen

Experimental
Denosumab 120 mg SC on days 1, 8, 15, 29 then Q4W (anti-RANKL monoclonal antibody)
Control
none (single-arm)

Population

Recurrent or unresectable giant cell tumour of bone (GCTB), RANK-ligand–driven osteoclast-rich stromal tumor

Key finding

Near-universal histologic response validating RANKL as the central driver in GCTB. Redefined the disease as biologically targetable rather than purely surgical.

Source: PMID 20149736

Timeline

    Guideline citations

    • NCCN BONE (p.20)